PSNL Insider Trading
Insider Ownership Percentage: 4.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $37,446.97
Personalis Insider Trading History Chart
This chart shows the insider buying and selling history at Personalis by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Personalis Share Price & Price History
Current Price: $5.36
Price Change: ▲ Price Increase of +0.35 (6.99%)
As of 01/30/2025 05:00 PM ET
Personalis Insider Trading History
Personalis Institutional Trading History
Data available starting January 2016
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.
Read More on Personalis
Volume
606,443 shs
Average Volume
1,211,985 shs
Market Capitalization
$378.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.75
Who are the company insiders with the largest holdings of Personalis?
Who are the major institutional investors of Personalis?
Which institutional investors are selling Personalis stock?
During the previous quarter, PSNL stock was sold by these institutional investors:
- Sumitomo Mitsui Trust Group Inc.
- Green Alpha Advisors LLC
During the previous year, company insiders that have sold Personalis company stock include:
- Aaron Tachibana (CFO)
- Christopher M Hall (CEO)
- Richard Chen (EVP)
Learn More investors selling Personalis stock.
Which institutional investors are buying Personalis stock?
Within the last quarter, PSNL stock was acquired by institutional investors including:
- abrdn plc
- China Universal Asset Management Co. Ltd.
- SG Americas Securities LLC